TAMMY GILLETT: Open Payments
NPI 1962401265 · KINDER, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$826 in 52 payments from 14 companies in 2025. Trend: 2023 $477 · 2024 $990 · 2025 $826
Food & beverage: $826
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $192 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $139 |
| Sumitomo Pharma America, Inc. | 4 | $99 |
| Axsome Therapeutics, Inc. | 4 | $77 |
| Indivior Inc. | 3 | $58 |
| Lilly USA, LLC | 2 | $43 |
| Evofem Biosciences, Inc. | 5 | $41 |
| Lundbeck LLC | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $34 |
| Exact Sciences Corporation | 2 | $30 |
Products named: VRAYLAR, CAPLYTA, GEMTESA, Auvelity, SUBLOCADE, MOUNJARO, Phexxi, REXULTI.
Industry payments across LA — which companies pay providers there.
